Dawei Wu
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 26
- Cancer Immunotherapy and Biomarkers 8
- CAR-T cell therapy research 5
- Co-authors
- Haoyi Wang (20 shared papers)Jing Huang (5 shared papers)Hongnan Mo (7 shared papers)Haipeng Guo (14 shared papers)Dong Qu (4 shared papers)Bo Lan (6 shared papers)Xuelian Chen (5 shared papers)Weidong Qin (13 shared papers)
- Journals
- The Lancet Oncology (4 papers)Biochemical and Biophysical Research Communications (3 papers)PLoS ONE (3 papers)Acta Biochimica et Biophysica Sinica (2 papers)British Journal of Radiology (2 papers)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Dawei Wu
118 papers receiving 3.4k citations
Dawei Wu's Hit Papers
Peers
Comparison fields: 5 of 131
- Oncology 783
- Pulmonary and Respiratory Medicine 613
- Critical Care and Intensive Care Medicine 93
- Epidemiology 550
- Cancer Research 218
Countries citing papers authored by Dawei Wu
This map shows the geographic impact of Dawei Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawei Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawei Wu more than expected).
Fields of papers citing papers by Dawei Wu
This network shows the impact of papers produced by Dawei Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawei Wu. The network helps show where Dawei Wu may publish in the future.
Co-authors
The 25 scholars most cited alongside Dawei Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 126 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC Hit paper breakdown → | 2020 | 334 |
| 2 | 2019 | 197 | |
| 3 | 2018 | 165 | |
| 4 | 2014 | 164 | |
| 5 | 2016 | 146 | |
| 6 | 2019 | 137 | |
| 7 | 2019 | 134 | |
| 8 | 2018 | 134 | |
| 9 | 2022 | 101 | |
| 10 | 2021 | 93 | |
| 11 | 2015 | 83 | |
| 12 | 2023 | 77 | |
| 13 | 2019 | 70 | |
| 14 | 2018 | 65 | |
| 15 | 2021 | 60 | |
| 16 | 2018 | 58 | |
| 17 | 2019 | 53 | |
| 18 | 2015 | 48 | |
| 19 | 2014 | 42 | |
| 20 | 2019 | 40 |
About Dawei Wu
Dawei Wu is a scholar working on Oncology, Critical Care and Intensive Care Medicine, Cancer Research, Surgery and Epidemiology, having authored 126 papers that have together received 3.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (8 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers), Ethics in Clinical Research (7 papers), Sepsis Diagnosis and Treatment (6 papers), CAR-T cell therapy research (5 papers), Coronary Artery Anomalies (5 papers), Cancer Genomics and Diagnostics (5 papers) and Biomedical Ethics and Regulation (4 papers). The work is most often cited by research in Oncology (783 citations), Pulmonary and Respiratory Medicine (613 citations), Critical Care and Intensive Care Medicine (93 citations), Epidemiology (550 citations) and Cancer Research (218 citations). Dawei Wu has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Haoyi Wang, Jing Huang, Hongnan Mo, Haipeng Guo, Dong Qu, Bo Lan, Xuelian Chen, Weidong Qin, Chen Li and Binghe Xu. Their work appears in journals such as The Lancet Oncology, Biochemical and Biophysical Research Communications, PLoS ONE, Acta Biochimica et Biophysica Sinica and British Journal of Radiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.